CEL-SCI Corp - CVM STOCK NEWS

CEL-SCI Corporation (CVM) recently presented pivotal Phase 3 study data at the 10th European Congress on Head & Neck Oncology. The study focused on its investigational therapy, Multikine, for newly diagnosed locally advanced squamous cell carcinoma of the head and neck. Key findings show that Multikine added to standard care significantly improves overall survival rates: 65.3% for treated patients versus 49.7% for controls after five years. The company plans to submit a Biologics License Application to the FDA for regulatory approval based on results involving 352 patients. The study highlights the potential of Multikine in enhancing treatment outcomes for this patient population.

CEL-SCI Corporation (NYSE American: CVM) announced that it will present new data from its pivotal Phase 3 study on March 8, 2023, at the 10th European Congress on Head & Neck Oncology in Lisbon, Portugal. The study, the largest ever for newly diagnosed locally advanced squamous cell carcinoma of the head and neck, involved 928 patients and aimed to assess the investigational product Multikine before standard treatments. Multikine, which received Orphan Drug designation from the FDA, seeks to harness the immune system's potential before conventional therapies. A summary of the findings will be published after the presentation.

CEL-SCI Corporation (AMEX: CVM) announced its financial results for the quarter ending December 31, 2022. Key highlights include successful clinical outcomes for Multikine, with five patients achieving complete cancer clearance and 40 demonstrating significant tumor reduction. The company prepares to submit a Biologic License Application (BLA) to the FDA, as its Phase 3 study shows a median overall survival improvement of 46.5 months for Multikine patients. Financially, CEL-SCI reported a net operating loss of $7.7 million and $18 million in cash reserves.

CEL-SCI Corporation (NYSE American: CVM) reported fiscal year 2022 results, focusing on the submission of a Biologics License Application for its product, Multikine, targeting advanced primary head and neck cancer. The Phase 3 trial showed significant survival benefits, with a median overall survival improvement of 46.5 months. Financially, the company had a net operating loss of $36.1 million. As of September 30, 2022, CEL-SCI was holding $22.7 million in cash. Despite challenges, the company aims to expedite its regulatory submission and leverage positive trial outcomes.

CEL-SCI Corporation (NYSE American: CVM) announced significant progress regarding its investigational drug Multikine for treating locally advanced primary squamous cell carcinoma of the head and neck. The Phase 3 trial showed a median overall survival improvement of 46.5 months, with 62.7% of patients alive after five years. Multikine is positioned as a neoadjuvant therapy, unlike competitors’ treatments, which are for recurrent tumors. Despite challenges due to limited resources compared to larger firms, the company remains committed to advancing Multikine’s approval for patient benefit.

CEL-SCI Corporation (NYSE American: CVM) reported significant findings from its Phase 3 IT-MATTERS study at the ESMO Annual Congress on September 10, 2022. The investigational drug Multikine showed promising results in treating locally advanced primary head and neck cancer, with 5 patients achieving complete tumor response after 3 weeks of treatment, confirmed at surgery. Additionally, 40 patients exhibited partial tumor reductions exceeding 30%. The findings indicate that early responses to Multikine treatment are prognostic for overall survival, supporting the company's plans for a Biologics License Application to the FDA.

CEL-SCI Corporation (NYSE American: CVM) presented two posters at the European Society for Medical Oncology Congress on September 10, 2022, highlighting results from its pivotal Phase 3 IT-MATTERS study. This study, focusing on neoadjuvant Leukocyte Interleukin Injection for squamous cell carcinoma of the head and neck, showed early tumor response indicating overall survival benefits. Outcomes included 45 documented neoadjuvant responses, with significant advantages seen in lower risk patients, and promising biomarker analyses supporting Multikine efficacy.

CEL-SCI Corporation (NYSE American: CVM) reported significant results from its Phase 3 study of Multikine, an investigational cancer immunotherapy for head and neck cancer. The therapy demonstrated a notable reduction and elimination of tumors within three weeks for some patients. Furthermore, a nearly four-year median overall survival benefit was observed in the radiation-only group, with more than 80% of responders alive at the study's end. CEL-SCI plans to submit a major follow-up package to the FDA soon, addressing questions and comments received, highlighting the urgency for improved treatment options.

CEL-SCI Corporation (CVM) announced results from its pivotal Phase 3 IT-MATTERS trial for Multikine, an investigational immunotherapy for advanced primary head and neck cancer. The study demonstrated a 14.1% absolute overall survival (OS) advantage at five years for patients deemed lower risk for recurrence, with a median OS of 101.7 months compared to 55.2 months for standard treatment. Multikine showed a significant objective response rate and reduced death rates among responders. The proposed indication could benefit around 210,000 patients annually.